deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT00528970

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus After Ventral Hernia Repair

Sponsor: Bausch Health Americas, Inc.

Conditions Ileus
Interventions MOA-728 Placebo
Updated 9 times since 2017 Last updated: Aug 12, 2019 Started: Oct 17, 2007 Primary completion: Feb 5, 2008 Completion: Feb 5, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Ileus, this trial is completed. The trial is conducted by Bausch Health Americas, Inc. and has accumulated 9 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshotCompleted~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshotCompleted~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 9 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE3

Show 4 earlier versions
  1. Jun 2019 — Oct 2019 [monthly]

    Completed PHASE3

  2. Jun 2018 — Jun 2019 [monthly]

    Completed PHASE3

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bausch Health Americas, Inc.
  • Progenics Pharmaceuticals, Inc.
Data source: Bausch Health Americas, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .